Adamas Pharma (ADMS) Misses Q2 EPS by 12c

Adamas Pharma (NASDAQ: ADMS) reported Q2 EPS of ($0.93), $0.12 worse than the analyst estimate of ($0.81). Revenue for the quarter came in at $0 versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Adamas Pharma (ADMS) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance